VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP) (“Aurinia” or the “Company”) announced three presentations including the first scientific abstract of multi-targeted therapy (MTT) utilizing voclosporin in the treatment of lupus nephritis at the 53rd Annual ERA-EDTA congress to be held in Vienna, Austria from May 21st – 24th, 2016.
